[{"id":"e2e18e0d-d872-46fc-9331-6fc0c0e97f5b","acronym":"IMMCO-1","url":"https://clinicaltrials.gov/study/NCT05000294","created_at":"2021-08-11T14:55:29.843Z","updated_at":"2024-07-02T16:35:14.403Z","phase":"Phase 1/2","brief_title":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","source_id_and_acronym":"NCT05000294 - IMMCO-1","lead_sponsor":"University of Florida","biomarkers":" HER-2 • TMB • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HR negative + HER-2 positive","tags":["HER-2 • TMB • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HR negative + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Fotivda (tivozanib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"990e4a94-72d6-4d5f-95f4-7a77a3d8a9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01835223","created_at":"2021-01-18T08:10:14.418Z","updated_at":"2024-07-02T16:36:39.497Z","phase":"Phase 1b/2","brief_title":"Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01835223","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/11/2013","start_date":" 07/11/2013","primary_txt":" Primary completion: 12/24/2018","primary_completion_date":" 12/24/2018","study_txt":" Completion: 11/08/2019","study_completion_date":" 11/08/2019","last_update_posted":"2020-10-28"},{"id":"66bc3f88-573e-483d-a074-c5b181266d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297244","created_at":"2021-01-18T05:16:20.218Z","updated_at":"2024-07-02T16:36:39.586Z","phase":"Phase 2","brief_title":"A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01297244","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68","pipe":"","alterations":" ","tags":["HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2020-10-27"},{"id":"b9d91394-f027-438a-bab7-0e8b954d997e","acronym":"TIVO-1","url":"https://clinicaltrials.gov/study/NCT01030783","created_at":"2021-01-18T04:02:47.313Z","updated_at":"2024-07-02T16:36:54.226Z","phase":"Phase 3","brief_title":"A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01030783 - TIVO-1","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 517","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2019-10-28"},{"id":"3ede8ad2-acee-4e50-a570-83fc9035aab8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01782313","created_at":"2021-01-18T07:51:26.424Z","updated_at":"2024-07-02T16:36:55.886Z","phase":"Phase 2","brief_title":"A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas","source_id_and_acronym":"NCT01782313","lead_sponsor":"Northwestern University","biomarkers":" KDR • FLT1","pipe":" | ","alterations":" KDR expression • FLT1 expression","tags":["KDR • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression • FLT1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 03/06/2013","start_date":" 03/06/2013","primary_txt":" Primary completion: 05/27/2015","primary_completion_date":" 05/27/2015","study_txt":" Completion: 12/28/2016","study_completion_date":" 12/28/2016","last_update_posted":"2019-09-09"},{"id":"7bf5ec1b-340c-4f5a-8127-15da47ed09ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01058655","created_at":"2021-01-18T04:10:08.340Z","updated_at":"2025-02-25T15:50:50.271Z","phase":"Phase 1/2","brief_title":"RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01058655","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2017-04-13"}]